A Multicenter Double-blind, Randomized, Placebocontrolled Phase I/II Study to Determine the Safety, Tolerability, Potential Efficacy and Dose Finding of INP20, an Oral Formulation for Treatment of Immunotherapy in Peanut-allergic Patients
Latest Information Update: 08 May 2025
At a glance
- Drugs Peanut allergy immunotherapy (Primary)
- Indications Peanut hypersensitivity
- Focus Adverse reactions
- Sponsors InnoUp Farma
Most Recent Events
- 30 Apr 2025 Planned End Date changed from 1 Dec 2024 to 1 Sep 2025.
- 30 Apr 2025 Planned primary completion date changed from 1 Dec 2024 to 1 May 2025.
- 11 Sep 2024 Planned End Date changed to 1 Dec 2024.